oncology

Innovator drug deals involving Chinese biopharma reach $41.5 billion as licensing overtakes M&A for pipeline expansion, notes…

Bringing together leaders, researchers, and stakeholders in the life sciences sector, this event aims to showcase how Belgium and…

The BIRAC funding will enable comprehensive toxicology assessments, a critical step in preparing for IND submission with…

Zydus to handle NDA submission and commercialisation in the US; Synthon to lead development and manufacturing

ISB 2001 demonstrated an ORR of 83 per cent in heavily pretreated patients treated at active doses (0.05 mg/kg and higher)

Agreement focuses on global commercialisation of anti-cancer immunotherapy

Lupin expands oncology portfolio with the launch of a generic version of Doxil in the U.S.

Pratima Reddy, Country Speaker for Merck India & MD, Merck Specialties elaborates on the company’s partnerships with national…

Company aims to launch 20 new medicines by 2030, and reduce carbon emissions

According to the company’s statement, all EIRs are in place for their USFDA facilities